Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals IN (IN.TO)

Inmed Pharmaceuticals IN (IN.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 63,689
  • Shares Outstanding, K 172,134
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,521 K
  • 60-Month Beta 6.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.94
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.07
  • Most Recent Earnings -0.02 on 03/31/19
  • Next Earnings Date 05/15/19
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.02
  • Number of Estimates 1
  • High Estimate -0.02
  • Low Estimate -0.02
  • Prior Year -0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.33 +6.06%
on 06/21/19
0.46 -23.91%
on 05/28/19
-0.08 (-18.60%)
since 05/24/19
3-Month
0.33 +6.06%
on 06/21/19
0.59 -40.68%
on 04/01/19
-0.24 (-40.68%)
since 03/26/19
52-Week
0.30 +16.67%
on 12/27/18
1.08 -67.59%
on 09/10/18
-0.41 (-53.95%)
since 06/26/18

Most Recent Stories

More News
Studies Add Validity to Cannabis' Medical Capabilities

All over the world, the debate over cannabis' ability to replace traditional medicines goes on as more medicinal applications continue to emerge. A handful of countries have already adopted medical cannabis...

BKKSF : 0.1900 (-5.61%)
IMLFF : 0.2656 (-4.29%)
IVITF : 0.3017 (+1.51%)
XLY.VN : 0.720 (+1.41%)
IGC : 1.56 (-7.14%)
CBWTF : 0.5462 (+2.67%)
GENE.VN : 0.400 (-1.23%)
IN.TO : 0.35 (-5.41%)
TTT.VN : 0.310 (+6.90%)
InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

VANCOUVER , May 15, 2019 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform...

IMLFF : 0.2656 (-4.29%)
IN.TO : 0.35 (-5.41%)
InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019

TSX:IN OTCQX:IMLFF

IMLFF : 0.2656 (-4.29%)
IN.TO : 0.35 (-5.41%)
Consumer's Calls for Cannabis Legalization Continue as Plant's Versatility is Exhibited

Legalization efforts, which are ever present within the cannabis industry, have steadily attracted new consumers each year. In particular, Baby Boomers have seen a large influx of users over recent years;...

IMLFF : 0.2656 (-4.29%)
AREV.CN : 0.270 (-3.57%)
LDSYF : 0.2610 (+0.38%)
MYM.CN : 0.265 (+8.16%)
ALEAF : 0.7570 (+2.71%)
LDS.CN : 0.360 (+2.86%)
IN.TO : 0.35 (-5.41%)
MYMMF : 0.1920 (+4.35%)
ALEF.TO : 0.99 (+2.06%)
InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology

TSX: IN OTCQX: IMLFF

IMLFF : 0.2656 (-4.29%)
IN.TO : 0.35 (-5.41%)
InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program

Transition to INM-755 Expected to Improve the Probability of Development and Regulatory Success

IMLFF : 0.2656 (-4.29%)
IN.TO : 0.35 (-5.41%)
Consumers Turn to Newly Legalized CBD Products

Hemp is known to be associated with many diverse businesses such as those involved in industrial settings, consumer textiles, and more importantly, the cannabis industry. In 2017, the majority of hemp...

IMLFF : 0.2656 (-4.29%)
PURA : 0.0778 (unch)
WCVC : 0.0499 (+5.05%)
CNAB : 0.3200 (-5.19%)
PNAT : 0.0033 (unch)
WKULF : 0.0395 (unch)
POT.CN : 0.055 (unch)
FRLF : 0.1400 (-7.04%)
IN.TO : 0.35 (-5.41%)
USMJ : 0.0004 (unch)
Cannabis Markets are Expanding as Countries Eye Positive Tax Revenues

After many years of effort and research, cannabis is now widely considered a source of tax revenue for many U.S. states. The majority of these states have already passed a bill to legalize medical cannabis,...

IMLFF : 0.2656 (-4.29%)
BIOIF : 0.3371 (-4.85%)
CANN : 0.8350 (-2.91%)
BIO.CN : 0.450 (+1.12%)
MNTR : 0.3100 (-1.59%)
IN.TO : 0.35 (-5.41%)
HRVOF : 0.4990 (unch)
HVT.VN : 0.650 (+1.56%)
InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

TSX:IN OTCQX:IMLFF

IMLFF : 0.2656 (-4.29%)
IN.TO : 0.35 (-5.41%)
These Marijuana Stocks Should Be On Your Radar

CORAL GABLES, FL / ACCESSWIRE / February 5, 2019 / The market has managed to demonstrate its strength despite the fact that, at times, the conversation surrounding cannabis has been less than beneficial....

IMLFF : 0.2656 (-4.29%)
AMRS : 3.20 (-0.62%)
INNPF : 0.2210 (-15.13%)
NAB.CN : 0.360 (unch)
IN.TO : 0.35 (-5.41%)
PYX : 15.63 (-8.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 0.38
1st Resistance Point 0.38
Last Price 0.35
1st Support Level 0.36
2nd Support Level 0.34

See More

52-Week High 1.08
Fibonacci 61.8% 0.78
Fibonacci 50% 0.69
Fibonacci 38.2% 0.60
Last Price 0.35
52-Week Low 0.30

See More

Business Summary

InMed Pharmaceuticals Inc is a Canada based pre-clinical stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based therapies combined with drug delivery systems. It is focused on the treatment of diseases including pain and inflammation, dermatology,...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar